The medical device space is growing rapidly as new startups and investments from major players enter the market. Some of the most notable investors in medical devices include venture capital firms such as Kleiner Perkins Caufield & Byers, Sequoia Capital, and Accel Partners, as well as large companies such as Johnson & Johnson and Medtronic.
This influx of investment is driving innovation in the medical device space, with new devices and treatments being developed all the time. This growth is also creating opportunities for entrepreneurs, who can now launch their own medical device startups and access funding from major players.
Arnold offers thin cold-rolled titanium in a variety of CP Grades and alloys and an exceptionally broad range of thicknesses and widths for many applications, including medical devices, that require a strong, lightweight, corrosion-resistant, biocompatible material that is highly workable, ductile, and weldable.
This milestone indicates a new era for millions of women suffering from SUI, and results of this clinical study will contribute to the design and implementation of UroMems’ pivotal clinical trial in Europe and the U.S.
A Glasgow-based company focused on less invasive heart surgery treatment of structural heart disease is making its mark on the international stage.
Kidd & Company advises NextPhase is a class II and III medical device contract manufacturer of complex electromechanical devices, active implantable devices and single use disposables in North America. It provides design and engineering, manufacturing and assembly, quality and regulatory, and supply chain and logistics management services enabling its customers to bring low-to-medium volume complex medical devices to market.
Ultromics EchoGo ® Heart Failure is the first US Food and Drug Administration (FDA) cleared platform for detecting Heart Failure with Preserved Ejection Fraction (HFpEF), using a single view of an echocardiogram. The platform has the potential to catch disease earlier and get more patients on the pathway to treatment.
Norman Paradis MD, CPR Therapeutics Founder and CEO stated: “Receiving all three patents in one week is a wonderful coincidence that highlights the breadth of our innovation. We already knew that our existing patent portfolio was strong and provided a sound foundation for our future commercial efforts. Now it is even stronger. I believe any one of these patents could justifiably be called a breakthrough invention in and of itself.”